Darbepoetin use, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 42 445 8.9%
AusNZ D2(2002)
D3(2006) 165 473 34.0%
D3(2007) 132 429 32.5%
D4(2010) 93 243 37.0%
D4(2011) 154 328 45.3%
Belgium D2(2002) 42 508 8.2%
D3(2006) 109 476 21.9%
D3(2007) 147 386 37.6%
D4(2010) 201 417 44.9%
D4(2011) 199 395 48.9%
Canada D2(2002) 32 543 6.8%
D3(2006) 234 515 54.8%
D3(2007) 197 420 60.1%
D4(2010) 159 294 62.8%
D4(2011) 229 400 64.8%
France D2(2002) 73 432 17.9%
D3(2006) 238 510 46.3%
D3(2007) 313 503 61.8%
D4(2010) 192 311 58.1%
D4(2011) 215 380 54.3%
Germany D2(2002) 69 497 14.7%
D3(2006) 186 509 36.5%
D3(2007) 219 561 38.4%
D4(2010) 156 504 29.7%
D4(2011) 162 527 30.2%
Italy D2(2002) 50 479 12.5%
D3(2006) 162 458 37.8%
D3(2007) 190 469 43.3%
D4(2010) 151 448 34.2%
D4(2011) 166 471 34.0%
Japan D3(2006) 1 1,523 0.1%
D3(2007) 1 1,547 0.1%
D4(2010) 690 1,332 53.2%
D4(2011) 726 1,423 51.6%
Spain D2(2002) 55 559 10.0%
D3(2006) 187 618 30.5%
D3(2007) 195 507 37.2%
D4(2010) 181 536 33.3%
D4(2011) 169 497 34.7%
Sweden D2(2002) 93 512 16.4%
D3(2006) 143 512 23.9%
D3(2007) 168 473 34.2%
D4(2010) 124 379 33.2%
D4(2011) 149 409 33.4%
UK D2(2002) 95 524 16.0%
D3(2006) 249 401 64.4%
D3(2007) 212 321 55.5%
D4(2010) 165 312 46.7%
D4(2011) 170 372 44.6%
US D2(2002) 9 2,009 0.3%
D3(2006) 241 1,645 16.7%
D3(2007) 219 1,212 17.4%
D4(2010) 121 2,786 5.4%
D4(2011) 264 3,049 5.9%

Prescription in previous three months, among patients prescribed any ESA

Please see additional methodological information in the Data Sources and Methods section.